AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
Status:
Terminated
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
A phase II study testing the efficacy of combined AZD1775 with AraC or single agent activity
of AZD1775 in three arms: Arm A has subjects age 60 years or older who are newly diagnosed
with AML receiving the combination of the drugs; Arm B has subjects who are have
relapsed/refractory AML and HMA failure MDS patients being allocated to either the
combination Arm B or single agent AZD1775 Arm C.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health